The Maabarot-backed oral insulin developer has closed a $30m round featuring WuXi PharmaTech that will fund trials for two disorders.
WuXi Healthcare Ventures, a strategic investment subsidiary of pharmaceutical company WuXi PharmaTech, participated in a $30m series D round for Israel-based digestible insulin formulation developer Nutrinia today.
TPG Biotech, the life science investment branch of alternative asset management firm TPG, led the round, which included HIG BioHealth Partners, a subsidiary of private equity firm HIG Capital, as well as investment firm OrbiMed and venture capital firm Pontifax.
Nutrinia is developing an oral insulin formulation to treat intestinal malabsorption in preterm…